In recent years, the importance of the role of enhanced circulating FGF23 on the development of cardiac remodeling was thoroughly demonstrated in patients with CKD (34, 38–43) and end-stage renal disease (ESRD) (34, 35, 44). The gene discussed is FGF23; the disease is chronic kidney disease.